Drugs targeting the fatty acid synthase enzyme

Sagimet Biosciences is focused on developing innovative therapies targeting fatty acid synthase (FASN) inhibitors to address metabolic diseases linked to the overproduction of palmitate, particularly metabolic dysfunction-associated steatohepatitis (MASH). Their lead candidate, denifanstat, is an oral medication designed for once-daily administration, which has shown promising results in Phase 2 clinical trials, demonstrating a favorable pharmacokinetic profile and tolerability. The company is also investigating the potential of denifanstat and another candidate, TVB-3567, in treating acne and various cancers, where fatty acid metabolism is disrupted.

The company’s development pipeline includes ongoing clinical trials for denifanstat in MASH, with completed studies indicating its efficacy and safety. Additionally, Sagimet is exploring the use of denifanstat in oncology, specifically for solid tumors and recurrent glioblastoma. The strategic focus on FASN inhibitors highlights Sagimet's commitment to addressing significant unmet medical needs in metabolic and oncological disorders through targeted therapeutic approaches.

United States

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors.

Cancer

Digestive System Diseases

Sagimet Biosciences

Glioblastoma

Denifanstat w/ Bevacizumab

Small Molecule Pharmaceuticals

Denifanstat w/ Bevacizumab 

Acne

Denifanstat (ASC40)

Metabolic dysfunction-associated steatohepatitis

Denifanstat 

Non-alcoholic steatohepatitis

Denifanstat

Liver disease

Denifanstat  

TVB-3567

Denifanstat + Resmetirom

California - North

California

Therapeutic

Sagimet Biosciences

Company Details